{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:50:12Z","timestamp":1790628612800,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.12.040","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T20:27:13Z","timestamp":1547152033000},"page":"863-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Demonstrating vaccine effectiveness during a waning epidemic: A WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates"],"prefix":"10.1016","volume":"37","author":[{"given":"Kirsten S.","family":"Vannice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cristina","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary D.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Wilder-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-7536","authenticated-orcid":false,"given":"Philip R.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.12.040_b0005","unstructured":"World Health Organization. WHO global consultation on research related to Zika virus infection. Available at <http:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/zika-research\/en\/>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12916-018-1067-x","article-title":"Zika vaccines and therapeutics: landscape analysis and challenges ahead","volume":"16","author":"Wilder-Smith","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0015","unstructured":"World Health Organization. Zika vaccine development technical roadmap; 2018. Available at <http:\/\/www.who.int\/immunization\/research\/development\/Zika_Vaccine_Development_Technology_Roadmap_final_2018.pdf>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0020","unstructured":"VRC 705: a Zika virus DNA vaccine in healthy adults and adolescents. Available at <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03110770>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0025","unstructured":"Safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects. Available at <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03014089>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0030","unstructured":"World Health Organization. Zika virus disease. Available at <http:\/\/www.who.int\/csr\/disease\/zika\/en\/>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0035","doi-asserted-by":"crossref","first-page":"858","DOI":"10.15585\/mmwr.mm6731e1","article-title":"Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection \u2013 U.S. Territories and Freely Associated States, 2018","volume":"67","author":"Rice","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.12.040_b0040","unstructured":"World Health Organization. List of Blueprint priority diseases. Available at <http:\/\/www.who.int\/blueprint\/priority-diseases\/en\/>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax007","article-title":"Global travel patterns: an overview","volume":"24","author":"Glaesser","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw059","article-title":"Estimated global exportations of Zika virus infections via travellers from Brazil from 2014 to 2015","volume":"23","author":"Quam","year":"2016","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay044","article-title":"Zika in travellers 1947\u20132017: a systematic review","volume":"25","author":"Wilder-Smith","year":"2018","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1473-3099(16)30270-5","article-title":"Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study","volume":"16","author":"Bogoch","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2018.12.040_b0065","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1542\/peds.2010-1722E","article-title":"Food and Drug Administration regulation and evaluation of vaccines","volume":"127","author":"Marshall","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.12.040_b0070","unstructured":"WHO Expert Committee on Biological Standardization. Guidelines on clinical evaluation of vaccines: regulatory expectations. Tech Rep Ser; 2017 [No. 1004]."},{"key":"10.1016\/j.vaccine.2018.12.040_b0075","unstructured":"World Health Organization. Efficacy trials of ZIKV Vaccines: endpoints, trial design, site selection. Meeting report. Available at <http:\/\/www.who.int\/blueprint\/what\/norms-standards\/ZIKV_final_report_public_version.pdf>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0080","doi-asserted-by":"crossref","first-page":"ofy073","DOI":"10.1093\/ofid\/ofy073","article-title":"Asymptomatic prenatal Zika virus infection and congenital Zika syndrome","volume":"5","author":"Paixao","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.antiviral.2017.06.001","article-title":"Zika in the Americas, year 2: what have we learned? What gaps remain? A report from the Global Virus Network","volume":"144","author":"Aliota","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.12.040_b0090","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vacc Immunol CVI"},{"key":"10.1016\/j.vaccine.2018.12.040_b0095","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1093\/infdis\/jix433","article-title":"Clinical development strategies and considerations for Zika vaccine licensure","volume":"216","author":"Gruber","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.12.040_b0110","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/infdis\/jix678","article-title":"Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report","volume":"217","author":"Goncalves","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/infdis\/jiy164","article-title":"Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas","volume":"218","author":"Montoya","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0120","unstructured":"World Health Organization. Blood products and related biologicals catalogue. Available at <http:\/\/www.who.int\/bloodproducts\/catalogue\/en\/>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0125","unstructured":"World Health Organization. Main outcomes of the meeting of the WHO Expert Committee on Biological Standardization held from 29 October to 2 November 2018. Available at <https:\/\/www.who.int\/biologicals\/expert_committee\/ECBS_Executive_Summary_final_20_NOV_2018.IK.pdf>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12985-017-0750-4","article-title":"A guinea pig model of Zika virus infection","volume":"14","author":"Kumar","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.12.040_b0135","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1089\/scd.2016.0231","article-title":"Zika virus induced mortality and microcephaly in chicken embryos","volume":"25","author":"Goodfellow","year":"2016","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.vaccine.2018.12.040_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.019","article-title":"Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys","author":"Martinot","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.12.040_b0145","doi-asserted-by":"crossref","first-page":"e0190617","DOI":"10.1371\/journal.pone.0190617","article-title":"Ocular and uteroplacental pathology in a macaque pregnancy with congenital Zika virus infection","volume":"13","author":"Mohr","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.12.040_b0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41467-017-02499-9","article-title":"Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology","volume":"9","author":"Hirsch","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.12.040_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4163","article-title":"Durability and correlates of vaccine protection against Zika virus in rhesus monkeys","volume":"9","author":"Abbink","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.12.040_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","article-title":"Passive transfer of immune sera induced by a Zika virus-like particle vaccine protects AG129 mice against lethal Zika virus challenge","volume":"27","author":"Espinosa","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2018.12.040_b0170","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2018.12.040_b0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0180","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"issue":"e12","key":"10.1016\/j.vaccine.2018.12.040_b0185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine mediated protection against Zika virus-induced congenital disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.12.040_b0190","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0195","unstructured":"Food and Drug Administration. Summary basis for regulatory action \u2013 VAXCHORA; 2016. Available at <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM509681.pdf>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0200","unstructured":"WHO Expert Committee on Biological Standardization. Human challenge trials for vaccine development: regulatory considerations. Sixty-seventh report. Geneva: World Health Organization, Technical Report Series, No. 1004, annex 10; 2017."},{"key":"10.1016\/j.vaccine.2018.12.040_b0205","unstructured":"Shah, SK, Kimmelman, J, Lyerly, AD, Lynch, HF, McCutchan, F, Miller, FG, et al. Ethical considerations for Zika virus human challenge trials: report and recommendations. Available at <https:\/\/www.niaid.nih.gov\/sites\/default\/files\/EthicsZikaHumanChallengeStudiesReport2017.pdf>."},{"key":"10.1016\/j.vaccine.2018.12.040_b0210","article-title":"Persistence of Zika virus in body fluids \u2013 preliminary report","author":"Paz-Bailey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.12.040_b0215","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1093\/infdis\/jix491","article-title":"Zika vaccines: role for controlled human infection","volume":"216","author":"Durbin","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.040_b0220","unstructured":"World Health Organization. Individual Participant Data Meta-analysis of Zika-virus related cohorts of pregnant women (ZIKV IPD-MA). Available at <http:\/\/www.who.int\/reproductivehealth\/projects\/ZIKV.pdf>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18317134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18317134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:40:50Z","timestamp":1551721250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18317134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X18317134"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demonstrating vaccine effectiveness during a waning epidemic: A WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}